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Arsenic is a major environmental pollutant that
exists in soil and minerals; it readily enters the
groundwater system, contaminating drinking
water. The concentration of arsenic in ground-
water varies signiﬁcantly in different geographic
areas. Arsenic concentrations are highest in East
Asia, including Bangladesh; West Bengal,
India; and China (Kumagai and Sumi 2007;
Smith et al. 2000; Tchounwou et al. 2003).
Many efforts have been made to reduce arsenic
damage as exemplified by the guideline for
arsenic in drinking water set by the World
Health Organization (Smith and Smith 2004)
and by local governments. Nevertheless, a large
number of populations are still at risk of arsenic
exposure and are suffering from arsenic-
induced adverse effects, such as hypertension,
arteriosclerosis, diabetes, hyperkeratosis, neu-
ropathy, and skin, liver, bladder, and lung can-
cer (Kumagai and Sumi 2007; Smith et al.
2006; Steinmaus et al. 2000; Tseng 2002).
Clearly, the best way to protect humans from
arsenic-induced damage is to reduce arsenic
intake. However, it is not always practical
because many people have no choice but to
consume drinking water and rice heavily conta-
minated with arsenic, as these are their only
sources of food and water. Therefore, an alter-
native choice, of equal importance, is to subvert
the detrimental effects of arsenic by modulating
the body’s defense system.
Nuclear factor erythroid 2-related factor 2
(Nrf2) is a critical transcription factor that reg-
ulates a cytoprotective response. Many of its
downstream target genes are important in
maintaining the cellular antioxidant response
and xenobiotic metabolism. For example,
γ-glutamylcysteine synthetase (GCS) and the
xCT cysteine antiporter are the key enzymes
for synthesis of glutathione and maintenance
of cellular redox homeostasis (Chan and
Kwong 2000; Sasaki et al. 2002; Wild et al.
1999). Conjugating enzymes, such as gluta-
thione S-transferases (GSTs) and UDP-
glucuronosyl transferase, facilitate the removal
of toxic and carcinogenic chemicals by increas-
ing their solubility and excretion (Kobayashi
and Yamamoto 2006; Zhang 2006). Many
transporters such as multidrug resistance pro-
teins and p-glycoprotein are important in
uptake and removal of xenobiotics (Hayashi
et al. 2003; Maher et al. 2005; Vernhet et al.
2001; Xu et al. 2005). Activation of the Nrf2
signaling pathway is tightly regulated by
Kelch-like ECH-associated protein 1 (Keap1)
according to changes in the intracellular redox
state when cells are exposed to exogenous
stimuli. Under normal conditions, cells main-
tain low constitutive levels of Nrf2-target
genes through constant ubiquitination and
degradation of Nrf2, which is accomplished
by the Keap1-dependent E3 ubiquitin ligase
complex. Upon induction, Nrf2 is stabilized
because of impaired Keap1-E3 ubiquitin lig-
ase activity, which results in activation of the
Nrf2 signaling pathway (Cullinan et al. 2004;
Furukawa and Xiong 2005; Kobayashi et al.
2004; Sun et al. 2007; Zhang et al. 2004b).
Chemopreventive compounds are able to acti-
vate the Nrf2-dependent adaptive response
and thus confer protection against subsequent
toxic or carcinogenic damage (Jeong et al.
2006; Yates and Kensler 2007). 
In addition to the beneﬁcial antioxidants
and many chemopreventive compounds, the
Nrf2 signaling pathway can also be induced
by many harmful chemicals such as arsenic,
hydrogen peroxide, and even anticancer drugs
including cisplatin (Aono et al. 2003; He
et al. 2006; Massrieh et al. 2006; Pi et al.
2003; Purdom-Dickinson et al. 2007; Wang
et al. 2006). This paradox may be explained
by the balance between the induction of the
Nrf2 defensive response and the toxic out-
come elicited by a particular compound. The
most attractive chemopreventive compounds
are those that potentially induce the Nrf2-
dependent defensive response without elicit-
ing toxic effects, that is, those that tip the
balance toward the Nrf2-dependent beneﬁcial
response. In accordance with this notion,
many chemopreventive compounds extracted
from dietary sources or plants activate the
Nrf2-dependent response at low doses and do
not elicit detectable toxic effects. Nrf2 activa-
tors identified so far can be classified into
categories that include phenolic antioxidants
(caffeic acid, epigallocatechin-3-gallate, buty-
lated hydroxyanisole), dithiolethiones
(oltipraz, 3H-1,2-dithiole-3-thione), isothio-
cyanates (sulforaphane), and triterpenoids
[1-(2-cyano-3,12-dioxooleane-1,9[11]-dien-
28-oyl)imidozole] (Yates and Kensler 2007;
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BACKGROUND: Groundwater contaminated with arsenic imposes a big challenge to human health
worldwide. Using natural compounds to subvert the detrimental effects of arsenic represents an
attractive strategy. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is a
critical regulator of the cellular antioxidant response and xenobiotic metabolism. Recently, activa-
tion of the Nrf2 signaling pathway has been reported to confer protection against arsenic-induced
toxicity in a cell culture model. 
OBJECTIVES: The goal of the present work was to identify a potent Nrf2 activator from plants as a
chemopreventive compound and to demonstrate the efﬁcacy of the compound in battling arsenic-
induced toxicity. 
RESULTS: Oridonin activated the Nrf2 signaling pathway at a low subtoxic dose and was able to stabi-
lize Nrf2 by blocking Nrf2 ubiquitination and degradation, leading to accumulation of the Nrf2 pro-
tein and activation of the Nrf2-dependent cytoprotective response. Pretreatment of UROtsa cells with
1.4 µM oridonin signiﬁcantly enhanced the cellular redox capacity, reduced formation of reactive oxy-
gen species (ROS), and improved cell survival after arsenic challenge. 
CONCLUSIONS: We identified oridonin as representing a novel class of Nrf2 activators and illus-
trated the mechanism by which the Nrf2 pathway is activated. Furthermore, we demonstrated the
feasibility of using natural compounds targeting Nrf2 as a therapeutic approach to protect humans
from various environmental insults that may occur daily.
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doi:10.1289/ehp.11464 available via http://dx.doi.org/ [Online 21 May 2008]Zhang 2006). Up-regulation of the Nrf2-
dependent defense response has proved to be
beneﬁcial in reducing arsenic-induced toxicity
in a cell culture model (Wang et al. 2007).
Stable knockdown of endogenous Nrf2 using
Nrf2-shRNA rendered cells more sensitive to
arsenic-induced cell death. On the other
hand, pretreatment with chemicals that acti-
vate Nrf2 enhanced cell resistance to arsenic-
induced cell death. The present study
provides the framework of using natural com-
pounds to activate the Nrf2-dependent pro-
tective pathway to counteract arsenic-induced
damage.
In this article we report the identiﬁcation
of a novel class of Nrf2 activators. Oridonin,
also known as rubesecensin A, is a diterpenoid
purified from the Chinese medicinal herb
Rabdosia rubescens. As one of the important
traditional Chinese medicines, R. rubescens has
been used by Chinese doctors to treat swelling
of the throat, insect bites, snake bites, inﬂam-
mation of the tonsils, and cancer of the esopha-
gus, stomach, liver, prostate, and breast (Zhou
et al. 2007a). The active ingredients in
R. rubescens are rubesecensin A (oridonin) and
rubesecensin B. Currently the major research
focus on oridonin is in its antiproliferation and
antitumor activities. The anticancer activity of
oridonin is thought to rely on its ability to
inhibit cell growth, reduce angiogenesis, and
enhance apoptosis (Chen et al. 2005; Ikezoe
et al. 2003; Liu et al. 2004, 2006; Meade-
Tollin et al. 2004; Zhang et al. 2004a).
Oridonin inhibits cell growth and induces
apoptotic cell death in many cancer cell lines,
including leukemia (NB4, HL-60, HPB-ALL,
Kasumi-1), glioblastoma (U118, U138),
melanoma (A375-S2), cervical carcinoma
(HeLa), ovarian carcinoma (A2780, PTX10),
prostate carcinoma (LNCap, Du145, PC3),
breast carcinoma (MCF-7, MDA-MB231),
murine ﬁbrosarcoma (L929), and non–small-
cell lung carcinoma (NCI-H520, NCI-H460,
NCI-H1299) (Chen et al. 2005; Ikezoe et al.
2003; Liu et al. 2004, 2006; Zhang et al.
2004a). The reported doses needed for growth
inhibition and apoptosis vary significantly
among different groups using different cell
lines, ranging from 0.5 μM (0.18 μg/mL) in
Kasumi-1 cells to 56 μM (20.4 μg/mL) in
HPB-ALL cells (Liu et al. 2006; Zhou et al.
200b7). In addition, oridonin enhances the
efﬁcacy of the cancer drug cisplatin in mouse
sarcoma cells (Gao et al. 1993). 
Mechanistic studies have provided a
molecular basis by which oridonin inhibits
cell growth and induces apoptosis. Oridonin
induced p21 expression, resulting in cell cycle
arrest in LNCaP and NCI-H520 cells (Ikezoe
et al. 2003). Oridonin activated the caspase 3–
dependent apoptotic pathway through
up-regulation of Bax and down-regulation of
Bcl-2, which promotes release of cytochrome c
(Chen et al. 2005; Liu et al. 2006). Inhibition
of telomerase activity has been reported to be
another mechanism that contributes to the
anticancer function of oridonin (Liu et al.
2004). Because telomerase activity is absent in
normal somatic cells but is up-regulated in
cancer cells or tumor tissues, this allows ori-
donin to speciﬁcally target abnormal tissue. In
addition, total tyrosine kinase activity was
reduced in response to oridonin treatment (Li
et al. 2007). In addition to cancer cell lines, the
efﬁcacy of oridonin in vivo has been demon-
strated in a colorectal carcinoma cell HT29-
inoculated mouse model (Zhu et al. 2007).
More signiﬁcantly, a recent study using both
cell culture and mouse models demonstrated
that oridonin displayed a great antitumor activ-
ity speciﬁcally in acute myeloid leukemia with
the t(8;21) translocation between AML1 and
ETO genes. Mechanistically, oridonin induced
the caspase 3–dependent cleavage of the
AML1–ETO fusion protein, leading to an
accelerated apoptotic response (Zhou et al.
2007b).
Here, we report that oridonin belongs to a
novel class of Nrf2 activators. Similar to tert-
butylhydroquinone (tBHQ), it inhibits ubiq-
uitination and degradation of Nrf2, resulting
in stabilization of Nrf2 and activation of the
Nrf2 signaling pathway. Furthermore, the
chemopreventive activity of oridonin was
demonstrated using a previously established
arsenic-UROtsa cell model. Pretreatment of
UROtsa cells with 1.4 μM oridonin signifi-
cantly enhanced the cellular redox capacity,
reduced formation of reactive oxygen species
(ROS), and improved survival of UROtsa cells
after arsenic exposure.
Materials and Methods
Chemicals. Most chemicals, including sodium
arsenite, tBHQ, and Hoechst 33258, were
from Sigma Chemical Co. (St. Louis, MO,
USA). Rubescensin A (oridonin) was pur-
chased from LKT Laboratories Inc. (St. Paul,
MN, USA). 
Cell cultures. We obtained human MDA-
MB-231 breast carcinoma cells from American
Type Culture Collection (Manassas, VA,
USA). Cells were cultured in Eagle’s minimal
essential medium (MEM) supplemented with
10% fetal bovine serum (FBS), 2 mM
HEPES, and 6 ng/mL bovine insulin from
Sigma Chemical Co. UROtsa cells were gen-
erously provided by M.A. Sens and D. Sens
(University of North Dakota). UROtsa cells
were grown in Dulbecco’s modified Eagle’s
medium (DMEM) enriched with 5% FBS. All
mammalian cells were incubated at 37°C in a
humidiﬁed incubator containing 5% CO2. 
Establishment of a reporter cell line.
We purchased the luciferase plasmid,
pGL4.22[luc2CP/Puro] from Promega
(Madison, WI, USA). A 39-bp antioxidant
responsive element (ARE)-containing sequence
from the promoter region of the human
NAD(P)H quinone oxidoreductase 1 (NQO1)
gene was inserted into the cloning site of the
luciferase plasmid. The ARE-luciferase plasmid
was transfected into MDA-MB-231 cells using
Lipofectamine Plus from Invitrogen (Grand
Island, NY, USA) according to the manufac-
turer’s instructions. At 48 hr posttransfection,
cells were grown in medium containing
3 μg/mL puromycin for selection. Stable cell
lines were considered established once all the
cells in the negative control plate were killed.
Stable cell lines were continuously grown in
the MEM containing 3 μg/mL puromycin.
For the reporter gene assay, the ARE-luciferase
stable reporter cells were seeded the day before
and treated with different doses of test com-
pounds for 24 hr. Cells were lysed in extraction
buffer [0.1 M potassium phosphate and 1 mM
dithiothreitol (DTT)] by freezing and thawing
three times, and luciferase activities were meas-
ured in an assay buffer (25 mM glycylglycine,
15 mM magnesium sulfate, 500 μM ATP,
250 μM luciferin, and 250 μM coenzyme A)
using a BioTek Synergy 2 microplate reader
(Winooski, VT, USA). We performed the
reporter gene assay in triplicate and calculated
the mean ± SD.
Luciferase reporter gene assay. For the
dual luciferase reporter gene assay, MDA-
MB-231 cells were transfected with the same
ARE-luciferase plasmid along with the
renilla luciferase expression plasmid,
pGL4.74[hRluc/TK], from Promega. At
24 hr posttransfection, the transfected cells
were treated with compounds for 24 hr, and
both ﬁreﬂy and renilla luciferase activities were
measured with the dual luciferase reporter
assay system from Promega. Fireﬂy luciferase
activity was normalized to renilla luciferase
activity. The experiment was carried out in
triplicate and expressed as the mean ± SD. 
mRNA extraction. Total mRNA was
extracted from cells using TRIZOL reagent
(Invitrogen), and equal amounts of RNA were
reverse-transcripted to cDNA using the
Transcriptor First Strand cDNA synthesis Kit
(Roche, Indianapolis, IN, USA). The PCR
condition, as well as Taqman probes and
primers for Nrf2, NQO1, heme oxygenase-1
(HO-1), and GAPDH were reported previ-
ously (Wang et al. 2007). Brieﬂy, we obtained
the following Taqman probes from the uni-
versal probe library (Roche): hNrf2 (#70),
hNQO1 (#87), hHO-1 (#25), and hGAPDH
(#25). The following primers were synthesized
by Integrated DNA Technologies (Coralville,
IA, USA): hNrf2: forward (acacggtccacagct-
catc) and reverse (tgtcaatcaaatccatgtcctg);
hNQO1: forward (atgtatgacaaaggacccttcc)
and reverse (tcccttgcagagagtacatgg); hHO-1:
forward (aactttcagaagggccaggt) and reverse
(ctgggctctccttgttgc); and hGAPDH: forward
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caaattcgttgt).
Real-time reverse transcriptase-polymerase
chain reaction (RT-PCR). The real-time PCR
condition was as follows: one cycle of initial
denaturation (95°C for 10 min), 40 cycles of
ampliﬁcation (95°C for 10 sec and 60°C for
20 sec), and a cooling period (50°C for 5 sec).
The data presented are relative mRNA levels
normalized to GAPDH, and the value from
the untreated cells was set as 1. We used trip-
licate samples to determine the mean ± SD.
Antibodies and immunoblot analysis. We
purchased the antibodies for Nrf2, Keap1,
and β-actin from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Cells were lysed in a
sample buffer [50 mM Tris-HCl (pH 6.8),
2% SDS, 10% glycerol, 100 mM DTT,
0.1% bromophenol blue]. After sonication,
cell lysates were electrophoresed through an
SDS-polyacrylamide gel and subjected to
immunoblot analysis. For detection of the
ubiquitinated Nrf2 in vivo, cells were trans-
fected with expression vectors for hemagglu-
tinin (HA)-ubiquitin, Keap1, and Gal4-Neh2
(the N-terminal domain of Nrf2 containing
the ubiquitin conjugating sites). The trans-
fected cells were either left untreated or
treated with chemicals along with 10 μM
MG132 (Sigma Chemical Co.) for 4 hr. Cells
were lysed by boiling in a buffer containing
2% SDS, 150 mM NaCl, 10 mM Tris-HCl,
and 1 mM DTT. These lysates were then
diluted 5-fold in buffer lacking SDS and
incubated with anti-Nrf2 or anti-Keap1 anti-
bodies. Immunoprecipitated proteins were
analyzed by immunoblot with antibodies
directed against the HA epitope (Zhang and
Hannink 2003). 
Ubiquitination assay. To detect endoge-
nous Nrf2 ubiquitination, the UROtsa cells
were treated with 10 μM MG132 and lysed
and diluted in the same way. Nrf2 was
immunoprecipitated with an anti-Nrf2 anti-
body and subjected to immunoblot analysis
with an antiubiquitin antibody (Sigma
Chemical Co.).
Protein half-life measurement. To measure
the half-life of Nrf2, cells were either left
untreated or treated with oridonin for 4 hr. To
block protein synthesis, we added 50 μM cyclo-
heximide. Total cell lysates were collected at
different time points and subjected to immuno-
blot analysis with an anti-Nrf2 antibody. The
relative intensity of bands was quantified by
the ChemiDoc CRS gel documentation system
and Quantity One software from BioRad
(Hercules, CA, USA).
Transient transfection of siRNA and meas-
urement of glutathione concentration. We pur-
chased Nrf2-siRNA and the control siRNA
from Qiagen (Valencia, CA, USA). Transient
transfection of siRNA was performed using
HiPerFect Transfection Reagent according to
the manufacturer’s protocol (Qiagen).
Intracellular glutathione concentration was
measured using the QuantiChrom glutathione
assay kit from BioAssay Systems (Hayward,
CA, USA). All the procedures were carried out
according to the manufacturer’s instructions. 
ROS detection. For detection of ROS, we
pretreated cells with 1.4 μM oridonin for 24
hr, followed by As(III) treatment or As(III)
plus oridonin cotreatment for another 24 hr.
ROS levels were measured using dichloroﬂuo-
rescein (Sigma Chemical Co., 10 μg/mL ﬁnal
concentration) and ﬂow cytometry. 
Detection of cell viability. Cell viability was
measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT)
(Wang et al. 2007) and by colony formation
assays. We performed colony formation assays
in 35-mm plates with 200 UROtsa cells.
Attached cells were left untreated or were
treated with oridonin for 24 hr, followed by
treatment with different doses of As(III) for
another 48 hr. After exposure, the medium was
replaced with fresh medium, and cells were
incubated for 12–14 days. The cells were then
ﬁxed and stained with crystal violet (0.5% in
Du et al.
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Figure 2. Effects of oridonin on MDA-MB-231 cells. (A) An aliquot of cell lysates from the dual luciferase
reporter gene assay was subjected to immunoblot analysis with anti-Nrf2, anti-Keap1, and anti-β-actin.
(B) Total cell lysates from MDA-MB-231 cells treated with oridonin for 24 hr were subjected to immunoblot
analysis with anti-Nrf2, anti-Keap1, and anti-β-actin antibodies. (C) mRNA from similarly treated cells was
extracted and reverse transcribed into cDNA prior to real-time PCR analysis for detection of mRNA for
Nrf2 (top), NQO1 (center), and HO-1 (bottom). 
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Figure 1. (A) Structure of the diterpenoid oridonin.
(B, C) Luciferase reporter gene assays in MDA-MB-
231 cells expressing ARE-luciferase. (B) Luciferase
activity showing oridonin as an Nrf2 activator using
a high-throughput screening system. The stable
MDA-MB-231 cells expressing ARE-luciferase were
seeded in 96-well plates; cells were grown to 90%
confluence and treated with oridonin for 24 hr
before analysis of luciferase activity. (C) Luciferase
activity in MDA-MB-231 cells cotransfected with a
plasmid containing an ARE-luciferase reporter gene
and a plasmid encoding renilla luciferase driven by
the herpes simplex virus thymidine kinase promoter.
The transfected cells were treated with oridonin for
24 hr prior to measurement of firefly and renilla
luciferase activities in cell lysates. All luciferase
reporter gene assays were run in triplicate and
expressed as mean ± SD.
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C95% ethanol), and the colonies in each plate
were counted. 
Detection of cell death. For detection of
apoptotic cell death, we used two different
methods: a) Annexin V-FITC apoptosis detec-
tion (Sigma Chemical Co.), and b) Hoechst
staining (1 μg/mL) for detection of the con-
densed nuclei. All experiments were conducted
in triplicate and expressed as mean ± SD. The
statistical signiﬁcance was determined by the
Student’s t-test.
Results
Identiﬁcation of oridonin as an Nrf2 activator.
Using the stable ARE luciferase reporter cell
line derived from MDA-MB-231 cells com-
bined with a 96-well high-throughput screen-
ing system established in our laboratory, we
identiﬁed a novel Nrf2 activator that belongs
to the class of diterpenoids (Figure 1A). The
MDA-MB-231 cell line was used to show
Nrf2 activation for two reasons: ﬁrst, MDA-
MB-231 cells can be easily transfected; and
second, the Nrf2 pathway is most sensitive in
this cell line in response to Nrf2-inducers.
Oridonin induced transcription of the ARE-
dependent luciferase gene in a dose-dependent
manner in this stable cell line (Figure 1B). To
conﬁrm oridonin activation of Nrf2 using the
high-throughput screening method, we also
performed a dual luciferase reporter gene assay
in which we included a renilla luciferase gene
as an internal control for transfection efﬁciency
and for toxicity induced during oridonin expo-
sure. Consistent with the data obtained from
the high-throughput screening, oridonin
induced the ARE-dependent luciferase activity
in a dose-dependent manner (Figure 1C).
Slight induction (1.5-fold) was observed at as
low as 1.4 μM and reached maximum induc-
tion (11.3-fold) at 14 μM. There was no obvi-
ous toxicity at 14 μM, as judged by cell
morphology and renilla luciferase activity.
Oridonin activated the ARE-dependent
response primarily through up-regulation of
the Nrf2 protein level. Previous studies have
demonstrated that ARE-dependent reporter
gene activity correlated very well with the pro-
tein level of Nrf2. Therefore, we used the
same cell lysates from the dual luciferase
reporter gene assay for immunoblot analysis
for detection of Nrf2, Keap1, and β-actin.
Although the Keap1 levels remained constant,
oridonin enhanced the levels of Nrf2 protein
in a dose-dependent manner, with the highest
induction at 14 μM (Figure 2A). During the
reporter gene assay, any doses > 14 μM caused
marked toxicity, as indicated by an increased
number of rounded and ﬂoating cells. A large
body of literature indicates that the antitumor
activity of oridonin relies on its ability to
inhibit cell growth and to induce cell death
(Zhou et al. 2007a). Because Nrf2 regulates a
cellular survival response, we envisioned that
treatment with high doses of oridonin could
inhibit Nrf2, allowing cells to undergo cell
death. Therefore, we tested Nrf2 protein levels
in response to high doses of oridonin. After
treatment of MDA-MB-231 cells with differ-
ent doses of oridonin for 24 hr, we collected
all cells, including floating cells. Equal
amounts of proteins were subjected to
immunoblot analysis with Nrf2, Keap1, and
β-actin antibodies. Interestingly, at doses
> 28 μM, Nrf2 protein levels decreased in a
dose-dependent manner, whereas the expres-
sion of Keap1 and β-actin had no signiﬁcant
change (Figure 2B, lanes 7–9). Previously, it
has been demonstrated that Nrf2 activators,
including tBHQ, induce the Nrf2 signaling
pathway primarily through stabilization of the
Nrf2 protein, rather than up-regulation of its
mRNA (Nguyen et al. 2003).
Next, we measured mRNA expression of
Nrf2 and its target genes, NQO1 and HO-1, in
response to oridonin using real-time RT-PCR.
Nrf2 mRNA increased slightly in a dose-
dependent manner in response to oridonin,
whereas tBHQ had no effect (Figure 2C, top
panel). As expected, mRNA of NQO1 and
HO-1 were induced signiﬁcantly by oridonin in
a dose-dependent manner (Figure 2C, center
and bottom panels). These results demon-
strate that oridonin is able to induce the
Nrf2 signaling pathway mainly through up-
regulation of Nrf2 at the protein level. 
Oridonin blocked Nrf2 ubiquitination
and enhanced Keap1 ubiquitination. tBHQ
enhances the Nrf2 protein level by interfering
with the Keap1-dependent ubiquitin conjuga-
tion process. Therefore, we tested the ability of
oridonin in modulating Nrf2 ubiquitination.
For this assay, we used Gal4-Neh2, a model
fusion protein previously used for the Nrf2
ubiquitination test (Zhang and Hannink
2003). In a manner similar to tBHQ, ori-
donin suppressed Nrf2 ubiquitination
(Figure 3A, left panel).
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Figure 3. Effects of oridonin on Nrf2 and Keap1 ubiquitination and protein half-life in MDA-MB-231 cells or UROtsa cells. Abbreviations: IB, immunoblot; IP, immuno-
precipitation; t1/2, half-life; Ub, ubiquitin. (A) MDA-MB-231 cells were cotransfected with expression vectors for HA-ubiquitin, a Gal4–Neh2 fusion protein, and Keap1;
the transfected cells were left untreated or treated with 8.4 µM oridonin or 100 µM tBHQ for 4 hr, along with 10 µM MG132. Cells were lysed in 2% SDS and immedi-
ately heated. Anti-Gal4 (left) and anti-Keap1 (center) immunoprecipitates analyzed by immunoblot with anti-HA antibodies for detection of the ubiquitin-conjugated
Neh2 or Keap1. (Right) Ubiquitination of endogenous Nrf2 assessed in UROtsa cells treated with DMSO, 8.4 µM oridonin, or 100 µM tBHQ for 4 hr, along with 10 µM
MG132; Nrf2 was immunoprecipitated with an anti-Nrf2 antibody, and ubiquitinated Nrf2 was detected with an anti-ubiquitin antibody. (B) Protein half-life in MDA-
MB-231 cells (left) and UROtsa cells (right) left untreated or treated with 8.4 µM oridonin for 4 hr. Cycloheximide (50 µM) was added to block protein synthesis. Cells
were lysed at the indicated time points, and lysates were subjected for immunoblot analysis with anti-Nrf2 and anti-β-actin antibodies (top). Intensity of the bands
was quantiﬁed using Quantity One software (bottom). In B, the bottom left and right graphs represent the bands in the top left and right, respectively.
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A BFurthermore, Zhang et al. (2005) showed
that tBHQ caused a shift of ubiquitination
from the substrate Nrf2 to the substrate adaptor
Keap1. As with tBHQ, oridonin treatment was
also effective in enhancing ubiquitination of
Keap1 (Figure 3A, center panel). These results
demonstrate that oridonin can induce a shift
of ubiquitination from Nrf2 to Keap1. One
of the major roles for ubiquitin conjugation
onto a protein is to target the protein for 26S
proteasome-mediated degradation. Next, we
measured the half-life of Nrf2 in the absence
or presence of oridonin. Half-life of the
endogenous Nrf2 protein in MDA-MB-231
cells was 19 min, whereas treatment with ori-
donin increased the half-life to 51 min
(Figure 3B, left panel). Taken together, these
results indicate that oridonin activates the
Nrf2 pathway by inhibiting ubiquitination
and degradation of Nrf2, leading to an
increase in Nrf2 protein level and activation of
the Nrf2-dependent response. 
Efﬁcacy of oridonin in protecting against
As(III)-induced toxicity. To test the feasibility
of using oridonin as a chemopreventive com-
pound to elicit the Nrf2-mediated protective
response to defend against environmental
Du et al.
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Figure 4. Effect of oridonin on UROtsa cells. Abbreviations: AnnV, Annexin V; DCF, 2',7'-dichlorodihydroﬂuorescein; PI, propidium iodide. (A) Immunoblot showing
Nrf2, Keap1, and β-actin in UROtsa cells treated with oridonin for 24 hr; cell lysates were collected and subjected to immunoblot analysis with anti-Nrf2, anti-
Keap1, and anti-β-actin antibodies. (B) Intracellular glutathione concentrations in UROtsa cells either untreated (control) or treated with 1.4 µM oridonin.
Concentrations were measured using the QuantiChrom glutathione assay kit; values shown are the mean ± SD of experiments run in triplicate. (C) ROS analysis in
UROtsa cells untreated or pretreated with oridonin for 24 hr and then further treated with As(III) or As(III) plus oridonin, respectively, for another 24 hr. ROS were
measured by dichloroﬂuorescein/ﬂow cytometry; values shown are the mean ± SD of experiments run in triplicate. (D) Cell survival in UROtsa cells untreated or
pretreated with 1.4 µM oridonin for 24 hr and then treated with As(III) in the absence or presence of 1.4 µM oridonin for another 48 hr; values shown are the mean
± SD of experiments run in triplicate. (D, top) Cell survival measured by the MTT assay. (D, center, at right) Immunoblot analysis showing Nrf2 protein levels in
UROtsa cells transfected with control siRNA or Nrf2-siRNA for 48 hr; Nrf2 protein levels were assessed by immunoblot analysis with an anti-Nrf2 antibody to con-
ﬁrm knockdown of Nrf2 expression. (D, center) Cell survival in Nrf2-siRNA transfected cells at 48 hr posttransfection measured by the MTT assay; 200 cells in
35-mm plates were pretreated and cotreated in the same manner as in the MTT assay. (D, bottom) Cell survival measured by the colony formation assay. Values
shown are the mean ± SD of experiments run in triplicate. (E) Apoptotic cell death in UROtsa cells untreated or pretreated with 1.4 µM oridonin for 24 hr and then
treated with As(III) in the absence or presence of 1.4 µM oridonin for another 48 hr. Apoptotic cell death was detected using Annexin V-FITC and ﬂow cytometry;
the mean ± SD was calculated from experiments run in triplicate (center). (E, bottom) Apoptois in UROtsa cells grown on cover slides were pretreated and
cotreated in the same way. Apoptotic cells were visualized by condensed nuclei using Hoechst staining; bars = 25 µm. The experiment was repeated, and similar
results were obtained.
*p < 0.05. **p < 0.01. 
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established model system for arsenic toxicity.
First, we determined activation of the Nrf2
pathway by oridonin in this cell line.
Ubiquitination of endogenous Nrf2 in
UROtsa cells was blocked by oridonin or
tBHQ treatment (Figure 3A, right panel).
Consistent with a decrease in ubiquitination
of Nrf2 in response to oridonin, the half life
of Nrf2 was increased from 10 min in the
untreated condition to 16 min in response to
oridonin treatment (Figure 3B, right panel).
Next, we determined the oridonin dose
range that induces Nrf2 protein in UROtsa
cells. Compared with MDA-MB-231 cells
(Figure 2B, lanes 2–7), UROtsa cells had a
narrow range of Nrf2 induction, from 1.4 to
14 μM (Figure 4A, lanes 3–6). Doses
> 14 μM appeared to be toxic, and induction
of Nrf2 was decreased (Figure 4A, lanes 7–9).
At 56 or 112 μg/mL, there was a decrease even
in the level of β-actin due to cytotoxicity
(Figure 4A, lanes 8 and 9). Nevertheless,
reduction of the Nrf2 protein was signiﬁcantly
more substantial, indicating that reduction of
Nrf2 at high doses may not be due solely to
reduced cell number. Based on this result, we
chose a low dose of oridonin (0.5 μg/mL) for
the protection assays. 
One of the major functions of Nrf2 is to
regulate an antioxidant response by up-
regulating intracellular antioxidants and genes
such as GCS and the xCT cysteine antiporter
that encode key enzymes in the synthesis of
glutathione. To confirm activation of the
Nrf2-dependent response by 1.4 μM ori-
donin, we compared the intracellular glu-
tathione level in the oridonin-treated cells
with that in untreated cells. Oridonin treat-
ment resulted in a signiﬁcant increase in the
glutathione level (Figure 4B). Thus, oridonin
is able to augment the cellular redox capacity,
which is the key mechanism in suppressing
oxidative stress–induced damage by environ-
mental insults. In the protection assays, we
used sodium arsenite [As(III)] to treat
UROtsa cells. We measured the ability of ori-
donin to alleviate As(III)-induced ROS
(Figure 4C). Treatment with 30 μM As(III)
for 24 hr increased the level of ROS signifi-
cantly, whereas 5.6 μM oridonin itself had no
effect. Pretreatment of cells with several doses
of oridonin for 24 hr and further cotreatment
with As(III) for an additional 24 hr resulted
in a signiﬁcant reduction of ROS levels, espe-
cially with 5.6 μM oridonin. These data
clearly demonstrate the efﬁcacy of oridonin in
suppressing oxidative stress imposed by
As(III) exposure. 
Finally, we assessed the effectiveness of
oridonin in protecting cells from acute cell
death in response to As(III). UROtsa cells
were left untreated or were pretreated with
1.4 μM oridonin. After a 24-hr pretreatment
period, several doses of As(III) were added to
both groups and incubated for an additional
48 hr before measuring total cell death using
both MTT and colony formation assays.
Pretreatment followed by cotreatment with
oridonin significantly improved cell survival
as judged by the MTT assay (Figure 4D, top
panel) and the colony formation assay
(Figure 4D, bottom panel). To conﬁrm that
protection against As(III)-induced cell death
was attributed to the activation of Nrf2 by
oridonin, the MTT assay was performed in
UROtsa cells that were treated with Nrf2-
siRNA for 48 hr. Immunoblot analysis con-
firmed the effectiveness of Nrf2-siRNA in
reducing Nrf2 expression (Figure 4D, center
panel). Inhibition of Nrf2 expression in
UROtsa cells reverted the MTT curve [i.e.,
oridonin lost its protection against As(III)
toxicity] and aggravated As(III)-induced cell
death (Figure 4D, center panel). This result
demonstrates that oridonin-mediated protec-
tion requires activation of the Nrf2 pathway. 
Apoptotic cell death was quantiﬁed using
Annexin V-FITC/ﬂow cytometry. Treatment
with 30 μM As(III) for 48 hr increased the
percentage of apoptotic cells, whereas pre-
treatment followed by cotreatment with
1.4 μM oridonin reduced apoptotic cell death
to a level comparable to the untreated cells
(Figure 4E, top and center panels). Apoptotic
cell death was not increased by 1.4 μM ori-
donin alone (data not shown). We used
Hoechst staining to detect condensed chro-
mosomes in the apoptotic cells. The number
of positive-stained cells increased after treat-
ment with 30 μM As(III), whereas pre-
treatment followed by cotreatment with
oridonin markedly reduced the number of
apoptotic cells (Figure 4E, bottom panel).
Together, these results demonstrate that a low
dose of oridonin is able to protect cells from
As(III)-induced damage, as illustrated by
reduced ROS and increased survival in
response to As(III).
Discussion
The pivotal role of Nrf2 in chemoprevention
has clearly been shown in Nrf2 null mice.
These mice express lower basal levels of the
Nrf2 target genes such as NQO1, GST, GCS,
UDP-glucuronosyltransferase, glutathione
peroxidase-2, and HO-1 (Chan and Kwong
2000; Cho et al. 2002; Hayes et al. 2000;
Kwak et al. 2001; McMahon et al. 2001). As
a consequence, these mice are more suscepti-
ble to toxic and carcinogenic challenges such
as butylated hydroxytoluene, benzo[a]pyrene,
diesel exhaust, aflatoxin B1, N-nitrosobutyl
(4-hydroxybutyl) amine, pentachlorophenol,
acetaminophen, ovalbumin, cigarette smoke,
and 4-vinyl cyclohexene diepoxide (Aoki et al.
2001; Chan et al. 2001; Chan and Kan 1999;
Enomoto et al. 2001; Hu et al. 2006; Iida
et al. 2004; Iizuka et al. 2005; Ramos-Gomez
et al. 2001; Rangasamy et al. 2005; Umemura
et al. 2006). These results provide the basis
for chemopreventive intervention targeting
the Nrf2 signaling pathway. Many previously
indentified, naturally occurring compounds,
including sulforaphane, epigallocatechin-3-
gallate, caffeic acid phenethyl ester, and cur-
cumin, have proved to be Nrf2 activators,
which further implies the importance of Nrf2
in chemoprevention (Jeong et al. 2006;
Nishinaka et al. 2007; Zhang 2006).
Identiﬁcation, validation, and optimization of
new Nrf2 activators are essential for the
development of effective dietary supplements
or therapeutic drugs that can be used to boost
the Nrf2-dependent adaptive system to pro-
tect humans from various environmental
insults. 
Oridonin represents a novel class of Nrf2
activators that has not been demonstrated pre-
viously. Mechanistic studies presented here
indicate that oridonin induced the Nrf2-
dependent response primarily by enhancing
the Nrf2 protein level. The increase in the
Nrf2 protein level in response to oridonin is
attributed mainly to the stabilization of Nrf2,
with minor contribution from increased
mRNA. Similar to tBHQ, oridonin is able to
block ubiquitination and degradation of Nrf2,
resulting in the prolonged half-life of Nrf2.
Furthermore, we demonstrated the effective-
ness of a low dose of oridonin (1.4 μM) in
eliciting the Nrf2-dependent cytoprotective
response in an As(III)-toxicity model. Low
doses of oridonin are able to enhance the
cellular reducing capacity by signiﬁcantly ele-
vating the reduced glutathione level, thus
inhibiting the formation of ROS, resulting in
increased survival in response to As(III) expo-
sure. Furthermore, glutathione is able to con-
jugate arsenic to facilitate arsenic excretion,
thereby reducing As(III) toxicity (Shinkai et al.
2006). In addition to GCS, which modulates
intracellular glutathione levels, other Nrf2
downstream genes, including GST, UDP-
glucuronosyl transferase, and multidrug resis-
tance proteins, also contribute to the
Nrf2-mediated protection against arsenic toxic-
ity (Hayashi et al. 2003; Kobayashi and
Yamamoto 2006; Maher et al. 2005; Vernhet
et al. 2001; Xu et al. 2005; Zhang 2006).
Although the present study shows only the
protection of oridonin against acute As(III)
toxicity, oridonin certainly can be applied to
other toxic and carcinogenic chemicals, because
oridonin induces the well-characterized Nrf2-
dependent defensive response. 
This cell-based study provides evidence
that low-dose oridonin can be used as a
chemopreventive compound that specifically
targets Nrf2. Further studies on the chemo-
preventive activity of oridonin in animal
models are needed. If oridonin is shown to
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has a great economic advantage because it can
easily be extracted from Rabdosia rubescens
“the Chinese grass.” In addition, identifica-
tion of diterpenoids as a new class of Nrf2
activators will broaden the choice for new
chemopreventive compounds. Moreover, the
diterpenoid structure can serve as a scaffold
for the development of chemopreventive
drugs. Identification of naturally occurring
diterpenoids or synthetic optimization of the
diterpenoid oridonin, which potently and
specifically induce the Nrf2 signaling path-
way, will greatly improve the efficacy of
chemopreventive drugs and decrease side
effects, which will have a profound impact on
human health. 
High doses of oridonin promote anti-
cancer activity by causing cell cycle arrest,
inhibiting proliferation, and inducing apop-
totic cell death. The dose range needed for
oridonin to exhibit anticancer activities in
these studies, conducted by different laborato-
ries with a variety of cancer cell lines, is very
broad, with 100-fold differences. Although
this may be due partially to the purity of ori-
donin used among groups, it largely indicates
a difference in sensitivity of cancer cells to the
oridonin-induced apoptotic response. In the
present study, the effect of oridonin in induc-
ing the Nrf2 protein level was assessed in two
different cell lines, breast carcinoma MDA-
MB-231 cells and immortalized but non-
transformed bladder urothelium UROtsa
cells. UROtsa cells showed a narrower win-
dow of Nrf2 induction in response to differ-
ent doses of oridonin. It is interesting to note
that oridonin induced Nrf2 protein and
reporter gene activity in a dose-dependent
manner to a certain point at which the Nrf2
protein level and the reporter gene activity
dropped suddenly. We observed an initial
decrease in Nrf2 protein in MDA-MB-231
cells and UROtsa cells at 56 μM and 28 μM
oridonin, respectively. This decrease in Nrf2
protein level in response to high doses of ori-
donin is not due solely to cell toxicity because
Keap1 or β-actin levels decreased only
slightly. Based on the important role of Nrf2
in cell survival, it is conceivable that Nrf2 has
to be repressed before the execution of cell
death. In support of this notion, Nrf2 has
been reported as a substrate of caspase 3
(Ohtsubo et al. 1999). The cleavage sites in
Nrf2 for caspase 3 have been identiﬁed. Based
on the Nrf2 induction proﬁle, it is remarkable
that oridonin functions as a chemopreventive
compound at low doses by activating the
Nrf2 cytoprotective pathway, whereas at high
doses, it activates apoptotic cell death and
concomitantly inhibits the Nrf2-dependent
survival pathway. Further studies are needed
to understand the molecular events that cause
the switch between life and death. 
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